RxDoctor Payments Data

John Marsh, MD

Family Medicine · Middlebrook, VANPI 1619997566

Payments from drug & device makers

$11,969in general payments, 2019–2025

Across 736 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$852
  • Pfizer$818
  • Amarin Pharma, Inc.$745
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$11,83599%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,969 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$614,203
Medicare patients
820
Services billed
9,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$205,845
OzempicSemaglutide76$110,274
JardianceEmpagliflozin105$108,959
FarxigaDapagliflozin Propanediol109$101,179
XareltoRivaroxaban78$85,057
MounjaroTirzepatide53$69,206
OxycontinOxycodone Hcl12$33,984
VerquvoVericiguat24$28,295
JanuviaSitagliptin Phosphate31$27,369
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,820
VascepaIcosapent Ethyl35$12,345
ShingrixVaricella-Zoster Ge/As01b/Pf53$11,602
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,079
Celecoxib311$9,685
AbrysvoRsv Vacc, Pref A And Pref B/Pf30$9,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$818$215,513254 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,113$119,961142 claims
Novo NordiskOzempic$1,205$110,27476 claims
Boehringer IngelheimJardiance$193$108,959105 claims
Johnson & JohnsonXarelto$555$85,05778 claims
Lilly USA, LLCMounjaro$852$69,20653 claims
MerckVerquvo, Januvia$742$55,66455 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arnuity Ellipta$228$40,246104 claims
Astellas Pharma US IncMyrbetriq$224$5,03811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Middlebrook

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →